<DOC>
	<DOCNO>NCT02371161</DOCNO>
	<brief_summary>A phase II prospective , non-randomized study . The study aim evaluate feasibility activity high-dose therapy stem cell elderly patient aggressive lymphoma relapse FIT resistant first line therapy .</brief_summary>
	<brief_title>Phase II High-dose Therapy Elderly Patients With Relapsed Aggressive NHL Resistant First Line Therapy</brief_title>
	<detailed_description>The study aim evaluate toxicity activity therapeutic approach high dos support peripheral blood stem cell ( PBSC ) patient age ≥ 65 ≤75 year , chemosensitive relapse refractory therapy first line term event free survival ( EFS ) treatment relate mortality ( TRM )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Diagnosis NHL relapse refractory pt age ≥ 65 ≤75 ECOG performance status &lt; 2 FIT patient ( Instrumental Activity Daily Living ( IADL ) =8 , Activity Daily Living ( ADL ) =6 , Cumulative Illness Rating Scale ( CIRS ) =0 SCORE=34 , &lt; 5 SCORE=2 ) evaluable disease RT since 3 week absolute neutrophil count &gt; = 1500/mm3 platelet &gt; = 100.000/106L Creatinin &lt; = 1.5 mg/dL clearance &gt; 40 ml/min/24 h bilirubins &lt; =2 mg/dL force expiratory volume &gt; 50 % arterial pressure O2 &gt; 70 mmHg neoplastic disease Life expectancy &gt; 3 month sign informed consent HBV+ HCV+ HIV+ NSC involvement medullar infiltration &gt; 20 % chemotherapy radiotherapy cardiac disease alteration liver kidney function infection demented patient compliance depress pt Frail Unfit pt</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>